Go to
JCI Insight
Abstract
Chronic pain is a debilitating condition that affects up to 1.5 billion people globally. Advancing pain management depends on a thorough understanding of the types of pain experienced by patients and the underlying mechanisms driving it. N-type calcium channels play a crucial role as therapeutic targets for managing chronic pain. In this issue of the JCI, Tang et al. introduce C2230, an N-type calcium channel blocker that inhibited CaV2.2 channels during high frequency stimulation with little effect on other ion channels in the pain pathway across multiple models. C2230 offers a promising analgesic for use in therapeutic intervention.
Authors
Maria A. Gandini, Gerald W. Zamponi
Figure 1
C2230 blocks N-type calcium channel and inhibits pain.
Options:
View larger image
(or click on image)
Download as PowerPoint
N-type calcium channels are expressed in the primary afferent pathways that innervate the skin, originating from dorsal root ganglion (DRG) neurons and their synaptic nerve terminals in the spinal dorsal horn. C2230 given to rodents using any of three different routes prevented calcium entry via CaV2.2 N-type calcium channels. The treatment led to analgesia of pain in three pain models.
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)